MSK Biomarker Ctte: Difference between revisions

Latest revision as of 16:43, 21 December 2023

Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD

The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.

Approved call summaries:

MSK Biomarker Committee Call Summaries Archive

@@ Line 1: / Line 1: @@
-:Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
+Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
-:Secretary: Susan Weinmann
+* [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster]
-:[[Media:QIBA MSK Roster.pdf|'''Roster''']]
 The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
-==Meetings/Call Summaries==
+==Meetings==
-*[[MSK Biomarker Committee Call Summaries]]
-==Working Documents==
+'''Approved call summaries:'''
+*[[Media:2023_12-12_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|December 12, 2023]]
+*[[Media:2023_10-24_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|October 24, 2023]]
+*[[Media:2023_09-26_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|September 26, 2023]]
+'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''
+==Profile Documents==
+*[[Media:QIBA_Profile_MSK-Cartilage-Stage2_Profile.pdf|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile]]
+*[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile]]
 ==Statistical Reference Documents==